logo-loader
viewBiocept Inc

Full interview: Biocept unveils revenue lift in 2Q earnings, bolsters IP portfolio

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the liquid biopsy provider reported a 45% boost in revenue during the second quarter of 2019, compared with the same period a year ago, driven largely by an increase in its commercial samples.

What's more, Nall says, the California-based company has been awarded three new patents in the US, Canada, and Europe, to add to its intellectual property portfolio, bringing the total to 36 patents.

Quick facts: Biocept Inc

Price: 0.3135 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $13.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Biocept 'one of the first' liquid biopsy providers to detect...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the California-based company's Target Selector liquid biopsy tests are now available to detect cancer biomarkers in cerebrospinal fluid. Nall says the company has also managed to win a US patent for its liquid biopsy cancer testing...

6 days, 4 hours ago

2 min read